Clik here to view.
How Sanofi Could Start Off on the Right Foot in Cambridge
To: Chris Viehbacher, CEO, Sanofi Aventis From: The Boston Biotech Community Re: Making the Most of the Impending Merger Dear Mr. Viehbacher, In the heat of the discussions regarding an acquisition of...
View ArticleClik here to view.
How Google+ Could Transform Healthcare & Medicine
This post was co-authored by Rich Whalley, an associate at CBT Advisors. What could Google do if it had access to everyone’s health data? You’re probably already thinking a few things: 1. There’s no...
View ArticleClik here to view.
Big Pharma Attempts to Extend Own Lifespan by Activating Sirtuins
Can drugs that supposedly “activate” a controversial target—sirtuin proteins—stop or even reverse the aging process? A new report this week said “No.” According to this report, published Wednesday...
View ArticleClik here to view.
Biogen Idec Lets Stromedix Do The Hard Part
For anyone wondering about the value that can be added by entrepreneurs and venture capitalists to the drug discovery and development process, look no further than Stromedix. This venture-backed...
View ArticleClik here to view.
Genomes-R-Us: Is BGI now Complete?
The sad endgame in the acquisition of Complete Genomics (NASDAQ: GNOM) came last week: having failed to create a sustainable business, CGI was put up for sale in June of this year, culminating in a...
View ArticleClik here to view.
Shedding Baggage, Alnylam Turns a Corner
What convinces investors that a drug discovery company is likely to bring products to the market, and rewards to shareholders? It comes down to just a few things: Proprietary biology. Confident...
View ArticleClik here to view.
Why Deborah Dunsire’s Unusual Bet on Alzheimer’s Makes Sense
Just because a biotech company has landed a high-profile chief executive, does that mean its product is going to work? I’ve been asking myself that question in the wake of the unexpected July 11...
View ArticleClik here to view.
Biotech VCs, Stung by Startup Returns, Elbow into Royalty Financing
The new landscape for venture capital investing does not seem to leave much room for classic company formation. Investor after investor has shut down or moved beyond startups into what seem like...
View ArticleClik here to view.
Foundation’s IPO Isn’t Bubbly, It’s a Jolt for Genomic Diagnostics
Foundation Medicine, the Cambridge, MA-based cancer diagnostic company, reminded me of the 2000 genomics bubble when it went public this week. The company sold its IPO shares at $18, and the stock...
View ArticleClik here to view.
Futuristic “Human-on-Chip” Models Will Help Drug Development
The pharmaceutical industry needs better scientific models for testing drugs before they get to the proving ground of human clinical trials. Current lab dish models and animal testing models are...
View ArticleClik here to view.
Stealth Mode is the New Sweet Spot for Some Biotechs
This post was co-authored by Sultan Meghji. In biotech’s early days, telling a story to a wide audience used to be part of the path to success. Founders would share a compelling early narrative to...
View ArticleClik here to view.
It Had to be You: Why Roche Was The Lone Suitor For Foundation
The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it was acquiring a majority interest in Foundation...
View Article
